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Endorsement of International Consensus
Radiochemistry Nomenclature Guidelines
Philip Elsinga1*, Angelika Bischof Delaloye2, Arturo Chiti3,4, Stefaan Vandenberghe5, Francesco Giammarile6 and
Ignasi Carrio7
With the open letter published in EJNMMI Radiophar-
macy and Chemistry by an international working group of
experts, the EJNMMI journal family endorses the applica-
tion of the guidelines in contributions to the journals.
Attached to the letter by the working group is a three-
page summary highlighting the most relevant issues used
in the notation of radiopharmaceuticals and related
terms.
The full paper with all recommendations is published in
“Consensus nomenclature rules for radiopharmaceutical
chemistry—setting the record straight, Coenen, H.H., Gee
A.D. et al., Nuclear Medicine and Biology, volume 55, v–xi
(2017) (https://doi.org/10.1016/j.nucmedbio.2017.09.004)”.
All Editors-in-Chiefs of the EJNMMI journals strongly
recommend all manuscripts meet these guidelines upon
submission. In addition, all reviewers will be asked to be
aware of the guidelines and wherever possible to check
if the guidelines are followed.
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